Preliminary experience of tigecycline treatment for infection in children with hematologic malignancies
- 122 Downloads
Background Severe infection is life-threatening in children with hematologic malignancies and its treatment is challenging because of an increasing number of multidrug-resistant pathogens. Tigecycline has an expanded antibacterial activity spectrum; some successful cases of tigecycline treatment have been reported in the literature. Objective To examine the efficacy and safety of tigecycline in children. Setting Department of hematologic malignancies in a tertiary hospital. Method A retrospective chart review from May 1, 2012 to May 1, 2017. The patients were identified by the hospital information system and a custom-made Microsoft Excel 2007 database of patients was created to record demographic and medical data. Main outcome measure Efficacy and safety of tigecycline use in severe infection children with hematologic malignancies. Results Thirty-seven patients were enrolled and the predominant diagnosis was acute lymphoblastic leukemia. The median duration of tigecycline therapy was 9 days. Most prescriptions were empirical. Eighteen patients received a maintenance dose of 2 mg/kg q12 h, without a loading dose. Sulperazone was the most frequently prescribed concomitant drug. At the end of tigecycline therapy, improvement was observed in 48.7% of cases. After treatment, interleukin-10 levels notably decreased. The only reported adverse event was a case of tooth discoloration. Conclusion Tigecycline can be used as salvage therapy in children with hematologic malignancy and seems tolerable. Prospective controlled studies are required to definitively evaluate the efficacy and safety of tigecycline in children.
KeywordsHematologic malignancies Neutropenia Pediatrics Severe infections Tigecycline
The authors wish to thank Chanchan Hu and Lingfang Liang for their help with data collection. We also thank Professor Yongmin Tang in the Hematology department of our hospital for his advice.
This study was supported in part by grants from the Zhejiang Medical and Health Science and Technology Plan Project (2007B119), the Zhejiang Medical and Health Science and Technology Plan Project (2012KYB119), and the Natural Science Foundation of Zhejiang Province (LY12H19006).
Conflicts of interest
There are no conflicts of interest to declare.
- 3.Purdy J, Jouve S, Yan JL, Balter I, Dartois N, Cooper CA, et al. Pharmacokinetics and safety profile of tigecycline in children aged 8–11 years with selected serious infections: a multicenter, open-label, ascending-dose study. Clin Ther. 2012;34(2):496–507 e1. https://doi.org/10.1016/j.clinthera.2011.12.010.CrossRefPubMedGoogle Scholar
- 4.Wyeth Pharmaceuticals Inc. asoPI. TYGACIL- tigecycline injection, powder, lyophilized, for solution. 2005. http://labeling.pfizer.com/showlabeling.aspx?id=491. Accessed 02 Apr 2018.
- 5.Dinleyici EC, Yargic ZA, Bor O, Kiremitci A, Durmaz G. Tigecycline treatment of multi-drug-resistant Corynebacterium jeikeium infection in a child with relapsing and refractory acute lymphoblastic leukemia. Pediatr Blood Cancer. 2010;55(2):349–51. https://doi.org/10.1002/pbc.22527.CrossRefPubMedGoogle Scholar
- 6.Foresti S, Di Bella S, Rovelli A, Sala A, Verna M, Bisi L, et al. Tigecycline lock therapy for catheter-related bloodstream infection caused by KPC-producing Klebsiella pneumoniae in two pediatric hematological patients. Antimicrob Agents Chemother. 2015;59(12):7919–20. https://doi.org/10.1128/AAC.01855-15.CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Tugcu D, Turel O, Aydogan G, Akcay A, Salcioglu Z, Akici F, et al. Successful treatment of multiresistant Achromobacter xylosoxidans bacteremia in a child with acute myeloid leukemia. Ann Saudi Med. 2015;35(2):168–9. https://doi.org/10.5144/0256-4947.2015.168.CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Takeda T, Hatae Y, Nakadate H, Fujita K, Suzuki Y, Wagatsuma Y, et al. A multi-institutional study on the efficacy and toxicity of imipenem/cilastatin sodium in severe infections complicating hematological diseases and cancers in children. Study group of infectious diseases in pediatric hematology/oncology in Hokkaido. Jpn J Antibiot. 1993;46(5):388–96.PubMedGoogle Scholar
- 10.Zengin E, Sarper N, Kilic SC. Piperacillin/tazobactam monotherapy versus piperacillin/tazobactam plus amikacin as initial empirical therapy for febrile neutropenia in children with acute leukemia. Pediatr Hematol Oncol. 2011;28(4):311–20. https://doi.org/10.3109/08880018.2011.557144.CrossRefPubMedGoogle Scholar
- 11.Schwab KS, Hahn-Ast C, Heinz WJ, Germing U, Egerer G, Glasmacher A, et al. Tigecycline in febrile neutropenic patients with haematological malignancies: a retrospective case documentation in four university hospitals. Infection. 2014;42(1):97–104. https://doi.org/10.1007/s15010-013-0524-x.CrossRefPubMedGoogle Scholar
- 13.Salvatore CM, Techasaensiri C, Tagliabue C, Katz K, Leos N, Gomez AM, et al. Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia. Antimicrob Agents Chemother. 2009;53(4):1546–51. https://doi.org/10.1128/aac.00979-08.CrossRefPubMedPubMedCentralGoogle Scholar
- 14.von Seth M, Sjolin J, Larsson A, Eriksson M, Hillered L, Lipcsey M. Effects of tigecycline and doxycycline on inflammation and hemodynamics in porcine endotoxemia: a prospective, randomized, and placebo-controlled trial. Shock. 2015;43(6):604–11. https://doi.org/10.1097/SHK.0000000000000351.CrossRefGoogle Scholar
- 16.Iosifidis E, Violaki A, Michalopoulou E, Volakli E, Diamanti E, Koliouskas D, et al. Use of tigecycline in pediatric patients with infections predominantly due to extensively drug-resistant gram-negative bacteria. J Pediatr Infect Dis Soc. 2017;6(2):123–8. https://doi.org/10.1093/jpids/piw009.CrossRefGoogle Scholar
- 18.Dizbay M, Altuncekic A, Sezer BE, Ozdemir K, Arman D. Colistin and tigecycline susceptibility among multidrug-resistant Acinetobacter baumannii isolated from ventilator-associated pneumonia. Int J Antimicrob Agents. 2008;32(1):29–32. https://doi.org/10.1016/j.ijantimicag.2008.02.016.CrossRefPubMedGoogle Scholar